Editing Pfizer (section)

=== Internal medicine ===

Pfizer has a longstanding history in vaccines, contributing to breakthroughs in diseases like polio and smallpox. Currently, the company focuses on vaccines for pneumococcal and meningococcal diseases, influenza, respiratory syncytial virus (RSV), [[Lyme disease]], and [[Clostridioides difficile]].<ref>{{cite web |title=Pfizer reports durable second-season efficacy for RSV vaccine |author=Lisa Schnirring|date=29 February 2024|url=https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/pfizer-reports-durable-second-season-efficacy-rsv-vaccine |website=[[Center for Infectious Disease Research & Policy]] |access-date=27 March 2025}}</ref><ref>{{cite web |title=Lyme Disease Vaccine Reaches Completion of the Primary Series
|url=https://www.contagionlive.com/view/lyme-disease-vaccine-reaches-completion-of-the-primary-series |author=John Parkinson|date=19 July 2024|website=Contagion |access-date=27 March 2025}}</ref> It also invests in maternal and neonatal vaccines, [[cancer prevention]], and efforts to mitigate [[Hospital-acquired infection|hospital-acquired infections]]. It also works in advancing therapies for issues related to metabolic and cardiovascular health, including obesity, [[type 2 diabetes]], [[insulin resistance]], and non-alcoholic fatty liver disease (NAFLD).<ref>{{cite web |title=CDC Endorses Pfizer’s Maternal RSV Vaccine to Shield Newborns |url=https://respiratory-therapy.com/products-treatment/pharmaceuticals/us-pharmaceuticals/cdc-endorses-pfizers-maternal-rsv-vaccine-shield-newborns/ |website=Respiratory Therapy|date=26 September 2023|access-date=27 March 2025}}</ref>